{"podcast":{"title":"Rheumnow Podcast","slug":"rheumnow-podcast-587987","podcast_index_feed_id":587987,"rss_url":"https://feed.podbean.com/rheumnow/feed.xml","website_url":"https://rheumnow.podbean.com","image_url":"https://pbcdn1.podbean.com/imglogo/image-logo/3681760/avatars-WU0yPZs9aq9zc0Tz-z65PkA-original.jpg","author":"Dr. Cush","episode_count":999,"summary":"Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com","last_synced_at":"2026-07-16T02:31:22.000703+00:00","page_url":"https://stenobird.com/podcast/rheumnow-podcast-587987"},"episode":{"title":"DERM on RheumNow (April 2026)","slug":"derm-on-rheumnow-april-2026","published_at":"2026-05-01T11:08:20+00:00","page_url":"https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-april-2026","show_page_url":"https://stenobird.com/podcast/rheumnow-podcast-587987","url":"https://rheumnow.podbean.com/e/derm-on-rheumnow-april-2026/","audio_url":"https://mcdn.podbean.com/mf/web/2ykhesshnzbugwhy/DERM_on_RheumNow_April_2026_ar7gb.mp3","summary":"The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM In 2025 DTC TV ad spending by top 10 incr to $2.67 billion (up from $2.1 B). Rheum Drugs in top 3: 1. Skyrizi $440 million 2. Tremfya $431 M 3. Rinvoq $376 M https://t.co/EsWgUqUy9Z 2. Dermatology Salaries 2025 – Dermatology is top 10 at $448K according to Medscape; expected to go down -1% in 2026; derms made up 2% of survey group 37K MDs 3. Itch is common in Scleroderma (SSc) and not related to Dz duration. Study of 2173 Pts (~20K itch assessments), 87 F; mean age 55 yrs; 40% w/ diffuse SSc. Itch (moderate 4/10) seen in ~35% at all times https://t.co/QnT8d0xA5Z 4. Asia-Pacific Lupus study of Mucocutaneous activity (MC-A) in 4102 SLE pts. 36% had MC-A (rash 1055; alopecia 731; m ulcers 352); 15% persistently. MC-A assoc w/ W, smoking, +serologies, vasculitis, myositis, serositis, nephritis, NP-SLE https://buff.ly/D5fXJdY 5. Predictors of Calcinosis Cutis in Systemic Sclerosis 6. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB 7. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor…","meta_description":"The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other C…","key_points":[],"chapters":[],"topics":[],"duration_seconds":943,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/rheumnow-podcast-587987/episodes/derm-on-rheumnow-april-2026/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-april-2026.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}